• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从尿毒症毒素潴留到通过对流清除:我们了解得够多了吗?

From uremic toxin retention to removal by convection: do we know enough?

作者信息

Vanholder R, Meert N, Schepers E, Glorieux G

机构信息

Nephrology Section, University Hospital, Gent, Belgium.

出版信息

Contrib Nephrol. 2008;161:125-131. doi: 10.1159/000130657.

DOI:10.1159/000130657
PMID:18451668
Abstract

The uremic syndrome is defined by a complex clinical picture, characterized by the dysfunction of most organs which are affected by the retention of multiple solutes. Recent research has helped to unravel the pathophysiology and to identify several as yet unknown responsible compounds. In this publication, we summarize which compounds play the most important pathophysiologic role, and which dialysis strategies can be considered to decrease their concentration and improve outcomes. The main pathophysiologic role is played by molecules which are so-called 'difficult to remove by dialysis'. Essentially observational studies have suggested that enhancement of removal of these molecules, by improving convection (hemodiafiltration), creates an improvement of survival. The knowledge of uremic toxicity is still far from complete however, and we need extra information about responsible compounds and mechanisms, eventually leading to a classification of the most important culprits, to allow the development of even more efficient or specific removal strategies.

摘要

尿毒症综合征由复杂的临床表现所定义,其特征为多数器官功能障碍,这些器官受到多种溶质潴留的影响。近期研究有助于阐明其病理生理学,并识别出几种此前未知的致病化合物。在本出版物中,我们总结了哪些化合物发挥着最重要的病理生理作用,以及可以考虑哪些透析策略来降低它们的浓度并改善预后。主要的病理生理作用由所谓“难以通过透析清除”的分子发挥。本质上,观察性研究表明,通过改善对流(血液透析滤过)增强这些分子的清除,可改善生存率。然而,关于尿毒症毒性的知识仍远未完善,我们需要有关致病化合物和机制的更多信息,最终对最重要的罪魁祸首进行分类,以便开发出更高效或更具特异性的清除策略。

相似文献

1
From uremic toxin retention to removal by convection: do we know enough?从尿毒症毒素潴留到通过对流清除:我们了解得够多了吗?
Contrib Nephrol. 2008;161:125-131. doi: 10.1159/000130657.
2
Uremic toxins: do we know enough to explain uremia?尿毒症毒素:我们对其了解是否足以解释尿毒症?
Blood Purif. 2008;26(1):77-81. doi: 10.1159/000110570. Epub 2008 Jan 10.
3
What is new in uremic toxicity?尿毒症毒性有哪些新进展?
Pediatr Nephrol. 2008 Aug;23(8):1211-21. doi: 10.1007/s00467-008-0762-9. Epub 2008 Mar 7.
4
New insights in uremic toxins.尿毒症毒素的新见解。
Kidney Int Suppl. 2003 May(84):S6-10. doi: 10.1046/j.1523-1755.63.s84.43.x.
5
A bench to bedside view of uremic toxins.从实验台到病床:对尿毒症毒素的观察
J Am Soc Nephrol. 2008 May;19(5):863-70. doi: 10.1681/ASN.2007121377. Epub 2008 Feb 20.
6
Uremic toxicity: present state of the art.尿毒症毒性:当前技术水平
Int J Artif Organs. 2001 Oct;24(10):695-725.
7
[Uremic toxins: the case of protein-bound compounds].[尿毒症毒素:蛋白结合化合物的情况]
G Ital Nefrol. 2010 Sep-Oct;27(5):498-507.
8
Biochemical and clinical evidence for uremic toxicity.尿毒症毒性的生化及临床证据。
Artif Organs. 2004 Mar;28(3):248-53. doi: 10.1111/j.1525-1594.2004.47315.x.
9
Extracorporeal removal of uremic toxins: can we still do better?体外清除尿毒症毒素:我们还能做得更好吗?
Semin Nephrol. 2014 Mar;34(2):209-27. doi: 10.1016/j.semnephrol.2014.02.011. Epub 2014 Feb 18.
10
Should dialysis modalities be designed to remove specific uremic toxins?透析方式是否应设计用于清除特定的尿毒症毒素?
Semin Dial. 2009 Jul-Aug;22(4):454-7. doi: 10.1111/j.1525-139X.2009.00599.x.

引用本文的文献

1
Why High-Volume Post-Dilution Hemodiafiltration Should Be the New Standard in Dialysis Care: A Comprehensive Review of Clinical Outcomes and Mechanisms.为何高容量后稀释血液滤过应成为透析治疗的新标准:临床结局与机制的全面综述
J Clin Med. 2025 Jul 9;14(14):4860. doi: 10.3390/jcm14144860.
2
High volume online hemodiafiltration: a global perspective and the Brazilian experience.高容量在线血液透析滤过:全球视角和巴西经验。
J Bras Nefrol. 2024 Apr-Jun;46(2):e20230104. doi: 10.1590/2175-8239-JBN-2023-0104en.
3
Terminal Phase Components of the Clotting Cascade in Patients with End-Stage Renal Disease Undergoing Hemodiafiltration or Hemodialysis Treatment.
终末期肾病行血液透析滤过或血液透析患者凝血级联的终末相成分。
Int J Mol Sci. 2020 Nov 10;21(22):8426. doi: 10.3390/ijms21228426.
4
Hemodiafiltration and hemodialysis differently affect P wave duration and dispersion on the surface electrocardiogram.血液滤过和血液透析对体表心电图P波时限及离散度的影响不同。
Int Urol Nephrol. 2016 Feb;48(2):271-7. doi: 10.1007/s11255-015-1144-4. Epub 2015 Nov 11.
5
Hemodialysis and hemodiafiltration differently modulate left ventricular diastolic function.血液透析和血液透析滤过对左心室舒张功能的调节作用不同。
BMC Nephrol. 2013 Apr 2;14:76. doi: 10.1186/1471-2369-14-76.